Flupentixol and trifluperidol reduce interleukin-1β and interleukin-2 release by rat mixed glial and microglial cell cultures

Polish Journal of Pharmacology

Volumn 56, Issue 5, 2004, Pages 563-570

  Kowalski, Jan ^a   Labuzek, Krzysztof ^a   Herman, Zbigniew S ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Flupentixol; Glia; IL 1 ; IL 2; Trifluperidol

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; FLUPENTIXOL; INTERLEUKIN 1BETA; INTERLEUKIN 2; NEUROLEPTIC AGENT; TRIFLUPERIDOL;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIA CELL; INCUBATION TIME; INHIBITION KINETICS; MICROGLIA; NONHUMAN; RAT;

ANIMALS; CELLS, CULTURED; FLUPENTHIXOL; INTERLEUKIN-1; INTERLEUKIN-2; MICROGLIA; NEUROGLIA; RATS; RATS, WISTAR; TRIFLUPERIDOL;

EID: 12344256583     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Araujo D, Cotman C: Differential effects of interleukin-1 beta and interleukin-2 on glia and hippocampal neurons in culture. Int J Dev Neurosci, 1995, 13, 201-212.
2. Baker G, Santalo R, Blumenstein J: Effects of psychotropic agents upon the blastogenic response of human T-lymphocytes. Biol Psychiatry, 1977, 12, 159-169.
3. Bertini R, Garattini S, Delgado R, Ghezzi P: Pharmacological activities of chlorpromazine involved in the inhibition of tumor necrosis factor production in vivo in mice. Immunology, 1993, 79, 217-219.
4. Boukhris W, Kouassi E, Revillard J: Differential effects of mixed D1/D2 and selective D2 dopaminergic antagonists on mouse T and B lymphocyte proliferation and interleukin production in vitro. Immunopharmacol Immunotoxicol, 1988, 10, 501-512.
5. Chao C, Hu S, Close K, Choi C, Molitor T, Novick W, Peterson P: Cytokine release from microglia: differential inhibition by pentoxifylline and dexamethasone. J Infect Dis, 1992, 166, 847-853.
6. Chengappa KN, Ganguli R, Yang ZW, Shurin G, Brar JS, Rabin BS: Impaired mitogen (PHA) responsiveness and increased autoantibodies in Caucasian schizophrenic patients with the HLA B8/DR3 phenotype. Biol Psychiatry, 1995, 37, 546-549.
7. DeLisi LE, Goodman S, Neckers LM, Wyatt RJ: An analysis of lymphocyte subpopulations in schizophrenic patients. Biol Psychiatry, 1982, 17, 1003-1009.
8. DeLisi LE, King AC, Targum S: Serum immunoglobulin concentrations in patients admitted to an acute psychiatric in patients service. Br J Psychiatry, 1985, 145, 661-665.
9. Denicoff K, Rubinoff D, Papa M, Simpson C, Seipp C, Lotze M, Chang A et al.: The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med, 1987, 107, 293-300.
10. Fenton M: Review: transcriptional and post-transcriptional regulation of interleukin-1 gene expression. Int J Immunopharmacol, 1992, 14, 401-411.
11. Frei K, Siepl C, Groscurth P, Bodmer S, Schwerdel C, Fontana A: Antigen presentation and tumor cytotoxicity by interferon-gamma-treated microglial cells. Eur J Immunol, 1987, 17, 1271-1278.
12. Ganguli R, Brar JS, Chengappa KR, DeLeo M, Yang ZW, Shurin G, Rabin BS: Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. Arch Gen Psychiatry, 1995, 52, 668-672.
13. Ganguli R, Rabin BS, Kelly RH, Lyte M, Ragu U: Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann NY Acad Sci USA, 1987, 496, 676-685.
14. Ganguli R, Yang Z, Shurin G, Chengappa R, Brar JS, Gubbi AV, Rabin BS: Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res, 1994, 51, 1-10.
15. Giulian D, Li J, Li X, George J, Rutecki P: The impact of microglia-derived cytokines upon gliosis in the CNS. Dev Neurosci, 1994, 16, 128-136.
16. Hasko G, Szabo C, Nemeth Z, Lendvai B, Vizi E: Modulation by dantrolene of endotoxin-induced interleukin-10, tumor necrosis factor-a, and nitric oxide production in vivo and in vitro. Br J Pharmacol, 1998, 124, 1099-1106.
17. Hetier E, Ayala J, Denefle P: Brain macrophages synthesize interleukin-1 and interleukin-1 mRNAs in vitro. J Neurosci Res, 1988, 21, 391-397.
18. Hornberg M, Arolt V, Wilke I, Kruse A, Kirchner H: Productions of interferons and lymphokines in leukocyte cultures of patients with schizophrenia. Schizophr Res, 1995, 15, 237-242.
19. Kistrup K, Gerlach J, Aaes-Jorgensen T, Larsen N-E: Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Psychopharmacology, 1991, 105, 42-48.
20. Kong L, Lai C, Wilson B, Simpson J, Hong J: Protein tyrosine kinase inhibitors decrease lipopolysaccharide-induced proinflammatory cytokine production in mixed glia, microglia-enriched or astrocyte-enriched cultures. Neurochem Int, 1997, 30, 491-497.
21. Kowalski J, Blada P, Kucia K, Ławniczek T, Madej A, Belowski D, Herman ZS: In vitro immunomodulatory effects of haloperidol and perazine in schozophrenia. World J Biol Psychiatry, 2000, 1, 190-196.
22. Kowalski J, Blada P, Kucia K, Madej A, Herman ZS: Neuroleptics normalize increased release of interleukin-1β and tumor necrosis factor-a from monocytes in schizophrenia. Schizophr Res, 2001, 50, 169-175.
23. Lane H, Lin H, Hwu H, Jann M, Hu W, Chang W: Haloperidol plasma concentrations in Taiwanese psychiatric patients. J Formos Med Assoc, 1995, 94, 671-678.
24. Levine J, Susnovski M, Handzel ZT, Leykin I, Shnitzky M: Treatment of schizophrenia with an immunosuppressant. Lancet, 1994, 34, 59-60.
25. Leykin I, Mayer R, Shinitzky M: Short and long term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology, 1997, 37, 75-86.
26. Licinio J, Wong M: Elevated levels of interleukin-2 in neuroleptic-free schizophrenics. Am J Psychiatry, 1993, 150, 1408-1410.
27. Maes M, Bosmans E, Ranjan R, Vandoolaeghe B, Meltzer HY, Ley M, Berghmans R et al.: Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr Res, 1996, 21, 39-50.
28. Maes M, Meltzer HY, Bosmans E: Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiat Scand, 1994, 89, 346-351.
29. Masserini C, Vita A, Basile R, Morselli R, Boato P, Peruzzi C, Pugnetti L et al.: Lymphocyte subsets in schizophrenic disorders. Relationships with clinical, neuromorphological and treatment variables. Schizophr Res, 1990, 3, 269-275.
30. McAllister C, VanKammen D, Rehn T, Miler A, Gurklis J, Kelly M, Yao J, Peters J: Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry, 1995, 152, 1291-1297.
31. Moots R, Al-Saffar Z, Hutchinson D, Golding S, Young S, Bacon P, McLaughlin P: Old drug, new tricks: haloperidol inhibits secretion of proinflammatory cytokines. Ann Rheum Dis, 1999, 58, 585-587.
32. Muller N, Ackneihel M, Hofschuster E, Mempel W, Eckstein R: Cellular immunity. HLA-class I antigens and family history of psychiatric disorder in endogenous psychoses. Psychiatry Res, 1993, 48, 201-217.
33. Muller M, Empl M, Riedel M, Schwartz M, Ackneihel M: Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci, 1997, 247, 308-309.
34. Noy S, Achiron A, Laor N: Schizophrenia and autoimmunity: a possible etiological mechanism? Neuropsychobiology, 1994, 30, 157-159.
35. Pollmacher T, Hinze-Selch D, Mullington J, Holsboer F: Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors. Arch Gen Psychiatry, 1995, 52, 877-878.
36. Tsuneizumi T, Babb S, Cohen B: Drug distribution between blood and brain as a determinant of antipsychotic drug effects. Biol Psychiat, 1992, 32, 817-824.
37. Wilke I, Arolt V, Rothermundt M, Weitzsch Ch, Hornberg M, Kirchner H: Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci, 1996, 246, 279-284.
38. Zahn J, Moller T, Kettenmann H, Nolte Ch: Microglial phagocytosis is modulated by pro- and anti-inflammatory cytokines. Neuroreport, 1997, 8, 3851-3856.